<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02712424</url>
  </required_header>
  <id_info>
    <org_study_id>29001</org_study_id>
    <nct_id>NCT02712424</nct_id>
  </id_info>
  <brief_title>DAR-901 TB Booster Vaccine to Prevent TB in Adolescents</brief_title>
  <acronym>DAR-PIA</acronym>
  <official_title>A Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study of the Prevention of Infection With Mycobacterium Tuberculosis Among Adolescents Who Have Previously Received BCG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Muhimbili University of Health and Allied Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DAR-901 booster vaccine or placebo will be administered to adolescents in Tanzania primed&#xD;
      with BCG to determine if immunization reduces the risk of TB infection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DAR-901 whole cell booster vaccine to prevent TB infection in adolescents (&quot;DAR-PIA&quot;)&#xD;
&#xD;
      This is a Phase II, 3-injection, randomized, controlled trial of DAR-901 to be conducted in&#xD;
      13-15 year old adolescents in Tanzania previously immunized with BCG. DAR-901 is a whole cell&#xD;
      inactivated non-tuberculous mycobacterial vaccine manufactured from the Master Cell Bank of&#xD;
      SRL-172 that was used in the successful Phase III DarDar Trial in Tanzania. The goals are to&#xD;
      establish the safety and efficacy of DAR-901 in preventing infection with TB. The 1 mg dose&#xD;
      was selected during the current Phase I dose-escalation trial of DAR-901 in the US being&#xD;
      conducted by Dartmouth and Aeras. The 1 mg dose corresponds to the dose of SRL 172 used in&#xD;
      the DarDar Trial.&#xD;
&#xD;
      All subjects will be screened by the T-spot® IGRA (Oxford Immunotec, Oxford, England) for&#xD;
      evidence of TB infection. All screened subjects will have a structured interview to identify&#xD;
      risk factors for TB infection (=positive IGRA). IGRA-positive subjects will be referred for&#xD;
      further evaluation and will not be entered in the immunization phase of the trial.&#xD;
&#xD;
      It is estimated that 1000 adolescents will need to be screened to identify a total of 650&#xD;
      IGRA-negative adolescents in the immunization phase of the trial. Subjects will be and&#xD;
      randomized 1:1 to DAR-901 or saline control at 0, 2 and 4 months. Doses will be administered&#xD;
      by intradermal (ID) injection in the deltoid area. IGRA testing will be repeated before dose&#xD;
      2, at 14 months, and again at 24 months.&#xD;
&#xD;
      This three year study began in the first quarter of 2016 in Dar es Salaam, is funded by&#xD;
      GHIT-Japan and will be directed by Geisel School of Medicine at Dartmouth (PI, F. von Reyn)&#xD;
      with collaborators at Muhimbili University of Health and Allied Sciences (MUHAS) in Tanzania&#xD;
      and Tokyo Medical and Dental University in Japan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">February 1, 2020</completion_date>
  <primary_completion_date type="Actual">February 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>New Infection With Mycobacterium Tuberculosis</measure>
    <time_frame>3 years</time_frame>
    <description>New infection with TB is based on conversion of IGRA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Persistent New Infection With M. Tuberculosis</measure>
    <time_frame>3 years</time_frame>
    <description>New positive IGRA that is also positive on repeat ≥3 mos later</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">625</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>DAR-901</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.1 mL intradermal injection of 1 mg DAR-901</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.1 mL intradermal injection of sterile saline for human use</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DAR-901</intervention_name>
    <arm_group_label>DAR-901</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sterile saline placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Negative IGRA at baseline -&#xD;
&#xD;
        Exclusion Criteria: Pregnancy, serious underlying disease&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C Fordham von Reyn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Muhimbili University of Health and Allied Sciences</name>
      <address>
        <city>Dar es Salaam</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 14, 2016</study_first_submitted>
  <study_first_submitted_qc>March 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2016</study_first_posted>
  <results_first_submitted>February 10, 2021</results_first_submitted>
  <results_first_submitted_qc>April 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2021</results_first_posted>
  <last_update_submitted>April 17, 2021</last_update_submitted>
  <last_update_submitted_qc>April 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>C. Fordham von Reyn</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT02712424/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT02712424/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DAR-901</title>
          <description>0.1 mL intradermal injection of 1 mg DAR-901&#xD;
DAR-901</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>0.1 mL intradermal injection of sterile saline for human use&#xD;
Sterile saline placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="315"/>
                <participants group_id="P2" count="310"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="281"/>
                <participants group_id="P2" count="278"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DAR-901</title>
          <description>0.1 mL intradermal injection of 1 mg DAR-901&#xD;
DAR-901</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>0.1 mL intradermal injection of sterile saline for human use&#xD;
Sterile saline placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="315"/>
            <count group_id="B2" value="310"/>
            <count group_id="B3" value="625"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="315"/>
                    <measurement group_id="B2" value="310"/>
                    <measurement group_id="B3" value="625"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.1" spread="0.76"/>
                    <measurement group_id="B2" value="14.2" spread="0.75"/>
                    <measurement group_id="B3" value="14.15" spread=".755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="361"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="315"/>
                    <measurement group_id="B2" value="310"/>
                    <measurement group_id="B3" value="625"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Tanzania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="315"/>
                    <measurement group_id="B2" value="310"/>
                    <measurement group_id="B3" value="625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IGRA negative</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="315"/>
                    <measurement group_id="B2" value="310"/>
                    <measurement group_id="B3" value="625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>New Infection With Mycobacterium Tuberculosis</title>
        <description>New infection with TB is based on conversion of IGRA</description>
        <time_frame>3 years</time_frame>
        <population>Conversion from IGRA neg to pos</population>
        <group_list>
          <group group_id="O1">
            <title>DAR-901</title>
            <description>0.1 mL intradermal injection of 1 mg DAR-901&#xD;
DAR-901</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.1 mL intradermal injection of sterile saline for human use&#xD;
Sterile saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>New Infection With Mycobacterium Tuberculosis</title>
          <description>New infection with TB is based on conversion of IGRA</description>
          <population>Conversion from IGRA neg to pos</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="315"/>
                <count group_id="O2" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistent New Infection With M. Tuberculosis</title>
        <description>New positive IGRA that is also positive on repeat ≥3 mos later</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DAR-901</title>
            <description>0.1 mL intradermal injection of 1 mg DAR-901&#xD;
DAR-901</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.1 mL intradermal injection of sterile saline for human use&#xD;
Sterile saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Persistent New Infection With M. Tuberculosis</title>
          <description>New positive IGRA that is also positive on repeat ≥3 mos later</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="315"/>
                <count group_id="O2" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DAR-901</title>
          <description>0.1 mL intradermal injection of 1 mg DAR-901&#xD;
DAR-901</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>0.1 mL intradermal injection of sterile saline for human use&#xD;
Sterile saline placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="315"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <description>Active TB was defined as an SAE for purpose of this study</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="315"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="315"/>
                <counts group_id="E2" subjects_affected="142" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="53" subjects_affected="53" subjects_at_risk="315"/>
                <counts group_id="E2" events="73" subjects_affected="73" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="73" subjects_affected="73" subjects_at_risk="315"/>
                <counts group_id="E2" events="310" subjects_affected="69" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr C Fordham von Reyn</name_or_title>
      <organization>Geisel School of Medicine</organization>
      <phone>6036505000</phone>
      <email>fvr@dartmouth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

